An Introduction to Multiple Myeloma
Multiple myeloma (MM) is an incurable B-cell-derived haematological malignancy originating from the proliferation of long-lived plasma cells in the bone marrow This leads to bone marrow failure and subsequent anaemia, immune paresis and infection, bone pain and fractures, high calcium levels and kidney failure. Drug resistance is an emerging issue in the treatment of MM, as many patients become refractory to treatment. Histone deacetylase inhibitors are currently an available treatment option for MM due to the well characterized role that genetics and epigenetics play in drug resistance. Other common drug classes used include alkylating agents and anthracyclines, proteasome inhibitors, monoclonal antibodies and corticosteroids; however, due to the increased doses of corticosteroids required for treating MM compared with other conditions, the side effect profile is substantial, particularly in older patients. Following an initial induction combination therapy, autologous stem cell transplantation is often the next step in MM treatment. Future treatment directions are centred around targeted immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, which was approved in 2021 for patients with relapsed/refractory disease after receiving four or more prior lines of treatment. Novel CAR T-cell therapy targets are under investigation to mitigate issues with resistance and relapse, with data from a phase I clinical trial of bispecific CAR T-cell therapy targeting B-cell maturation antigen and CD38 showing promise.
Multiple Myeloma Content
The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
Learn about investigational protein degradation and immunomodulatory therapies in multiple myeloma.
- Recognize the unmet needs in patients with relapsed/refractory multiple myeloma
- Outline the rationale for therapies based on protein degradation and immunomodulation for the treatment of patients with relapsed/refractory multiple myeloma
- Evaluate the latest evidence for therapies based on protein degradation and immunomodulation for relapsed/refractory multiple myeloma and arrange for appropriate patients to be referred to available clinical trials
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).
- Interpret factors that must be balanced when choosing therapy for patients with RRMM who have relapsed following 1–3 prior lines of therapy
- Evaluate alternative treatment strategies for patients with RRMM following >3 prior lines of therapy
- Identify optimal sequencing strategies for patients with RRMM in both early- and later-line settings
The evolving treatment landscape in relapsed/refractory multiple myeloma
Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.
Advice for early career multiple myeloma specialists – María-Victoria Mateos
At touchHAEMATOLOGY we aim to support early career haematologists and oncologists. In this video a global leader in the field of multiple myeloma, María-Victoria Mateos, shares her advice on stating a successful career in this specialty. Disclosures: María-Victoria Mateos discloses the following – Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, […]
Reducing the burden of managing multiple myeloma with oral therapies
Multiple myeloma (MM) is a haematological cancer needing continuous, long-term management. Treatment is lifelong and involves numerous clinic visits to receive intravenous or parenteral drugs, and this is burdensome not just for patients but for providers, too. Indeed, the costs associated with treating and managing the condition are among the highest of all malignancies. MM […]
Strategies to address the challenges of CAR-T cell therapy in patients with multiple myeloma – María-Victoria Mateos
María-Victoria Mateos (University of Salamanca, Salamanca, Spain), leading expert in mulitple myeloma, shared her thoughts on the current challenges in CAR-T cell therapy and the strategies being investigated to address them. CAR-T therapy has introduced a new treatment modality to the triple-class refractory patient population, who had minimal effective treatment options previously. Disclosures: María-Victoria Mateos […]
María-Victoria Mateos: Bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma
We were delighted to speak with María-Victoria Mateos (University of Salamanca, Salamanca, Spain) about the recent updates in bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma. Disclosures: María-Victoria Mateos discloses the following – Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees […]
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
A multiple myeloma expert and a community oncologist discuss real-world evidence for frail/elderly patients and its application in practice.
- Explain the role and importance of real-world evidence (RWE) in supporting clinical decision making
- Outline the key RWE related to the treatment of elderly and frail patients with multiple myeloma
- Discuss the management of elderly and frail patients with multiple myeloma in clinical practice
Improving outcomes in multiple myeloma with new treatment targets
Watch a panel of experts discuss how novel targeted therapies are changing the treatment paradigm for multiple myeloma to achieve the best outcomes for patients.
- Recall the mechanisms of action and data for relapsed/refractory multiple myeloma treatments with novel agents
- Discuss the adverse event (AE) profiles of treatments with novel targets and how AEs could be managed in clinical practice
- Describe the possible role of agents with novel targets earlier in the multiple myeloma treatment pathway